Why the study?
It was unknown whether cumulative stent length, as a marker of lesion complexity, influences adverse clinical outcomes following complex CTO PCI.
Does bempedoic acid reduce in-stent restenosis and adverse cardiovascular outcomes in adults following percutaneous coronary intervention with drug-eluting stent implantation?
Cohort (n=2,308)
Yes
Does bempedoic acid reduce in-stent restenosis and adverse cardiovascular outcomes in adults following percutaneous coronary intervention with drug-eluting stent implantation?
In a real-world propensity-matched cohort, bempedoic acid use following DES implantation was associated with significantly lower risks of in-stent restenosis, mortality, and heart failure.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Agho et al. (2026) conducted a cohort in Post-PCI with drug-eluting stent (DES) implantation (n=2,308). Bempedoic acid vs. No bempedoic acid was evaluated on In-stent restenosis (ISR) (RR 0.43, 95% CI 0.30-0.63, p=<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: